8. Manso L, et al. ONSITE study: Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes. European Society for Medical Oncology (ESMO) meeting 2016, Poster: 246P
9. Ortega V, et al. MERIBEL STUDY: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts). European Society for Medical Oncology (ESMO) meeting 2016, Poster: 238P
10. Blay J, et l. Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) or LMS. European Society for Medical Oncology (ESMO) meeting 2016, Poster: 1401PD
11. National Cancer Institute at the National Institute of Health. Available at:http://www.cancer.gov/cancertopics/pdq/t... Accessed: September 2016
12. EUCAN 2015. Thyroid Cancer. Available at: http://eu-cancer.iarc.fr/EUCAN/Cancer.aspx?Cancer=35 Accesse... September 2016
13. Ljungberg B, et al. Epidemiology of Renal Cell Carcinoma. European Association of Urology, 2011; 60; 615-621
14. Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122:664-671
15. Okamoto K, et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Medicinal Chemistry Letter 2010
16. SPC Lenvima (updated June 2015). Available at: http://www.medicines.org.uk/emc/medicine... September 2016
17. SPC Kisplyx (updated September 2016). Available at: http://www.medicines.org.uk/emc/medicine... September 2016.
18. World Health Organisation. Atlas of Health in Europe. 2003. World Health Organization, Regional Office of Europe, Copenhagen, Denmark.
19. Pollock R. Soft tissue sarcomas, A volume in the American Cancer Society Atlas of Clinical Oncology Series 2012
20. National Cancer Institute. Adult soft tissue cancer survival rates.
Available at:http://www.cancer.org/cancer/sarcoma-adultsofttissuecancer/d... Accessed September 2016
21. George S, et al. Systemic treatment of metastatic soft tissue sarcoma. Available at:http://hgp.gob.ec/index.html/uptodate/co... Accessed September 2016
22. Cancer Research UK, Soft tissue sarcoma incidence statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/type... Accessed September 2016
23. SPC Halaven (updated August 2016). Available at: http://www.medicines.org.uk/emc/medicine... September 2016
24. Schöffski P, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. The Lancet 2016; DOI:http://dx.doi.org/10.1016/S0140-6736(15)01283-0
September 2016
Oncology-EU0042
CONTACT: Media Enquiries: Eisai: Cressida Robson / Ben Speller, +44 7908314 155 / +44 7908 409 416, Cressida_Robson@eisai.net /Ben_Speller@eisai.net; Tonic Life Communications: Alex Davies / CallumHaire, +44 7716 324 722 / +44 7867 429 637, Alex.Davies@toniclc.com /Callum.Haire@toniclc.com
